The prostate-specific antigen (PSA) biomarker test has a low level of selectivity for diagnosing PCa and tracking cancer development [4], whereas prostate biopsies can lead to both false-positive and false-negative results [2,5,6]. The gene discussed is KLK3; the disease is posterior cortical atrophy.